Hi Sillazze,
Neuren doesn't need to keep the priority review voucher to advance any of the four indications for NNZ-2591. As designated orphan drugs, they are already guaranteed priority review. If Arcadia wants to keep the voucher to advance one of its own drugs, they still need to pay Neuren one third of an agreed value. Jon confirmed this in the investor call earlier this week.
- Forums
- ASX - By Stock
- NEU
- Ann: Investor Presentation, 14 March 2023
Ann: Investor Presentation, 14 March 2023, page-54
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B |
Open | High | Low | Value | Volume |
$20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1024 | $20.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.53 | 285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10 | 20.100 |
1 | 480 | 20.080 |
3 | 174 | 20.000 |
1 | 150 | 19.980 |
1 | 434 | 19.940 |
Price($) | Vol. | No. |
---|---|---|
20.570 | 295 | 1 |
20.600 | 4094 | 1 |
20.610 | 13 | 1 |
20.650 | 2488 | 1 |
20.700 | 252 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |